CDK5RAP2 (CDK5 Regulatory Subunit Associated Protein 2)

This study provides a comprehensive framework for understanding sorafenib resistance in HCC, alongside a validated prognostic model that holds potential for clinical application.

Lastly, one tumor with a novel SRF::MYOCD fusion displayed morphologic features reminiscent of desmoplastic melanoma while exhibiting a combined neural and smooth muscle phenotype. Our data expands on the morphologic and molecular spectrum of fusion-driven hybrid peripheral nerve sheath tumors, including 5 previously undescribed fusions, and further expands on non-CNS schwannomas with VGLL3 fusions.

Our results highlight the specificity and selectivity of in vitro generated CDK5RAP2 scaffolds and identify a minimal set of components required for human PCM assembly and function. This minimal model offers a powerful tool for studying centrosome biology and dysfunction in human health and disease.

These findings suggest that diminution of mitotic PCM may be a cause of M-phase-specific generation of supernumerary centrioles in selected cancer cells. [Media: see text] [Media: see text] [Media: see text] [Media: see text].

Furthermore, cryo-electron tomography (cryo-ET) revealed that AKAP350 fibrillar clusters form a three-dimensional network of entangled filaments, a structure significantly altered by DNase-I treatment. Overall, our findings suggest AKAP350 forms fibrillar clusters that serve as nucleoprotein scaffolding complexes in human cells.

Our results highlight the specificity and selectivity of in vitro generated CDK5RAP2 scaffolds and identify a minimal set of components required for human centrosome assembly and function. This minimal centrosome model offers a powerful tool for studying centrosome biology and dysfunction in human health and disease.

This enabled a medium-throughput drug screen to identify Selumetinib and Fulvestrant, as inhibitors of glioma invasion in vivo. Thus, the Hi-Q approach can easily be adapted to reliably harness brain organoids' application for personalized neurogenetic disease modeling and drug discovery.

Our comprehensive analysis systematically explored BPH serum characteristics, proteomic profiles, and identified novel serum markers that may contribute to the understanding of BPH and facilitate early diagnosis and intervention.

Importantly, high protein levels of MORC2, RBM39 and Slug are strongly associated with metastasis and poor clinical outcomes of colorectal cancer patients. Taken together, our findings uncover a novel mechanism by which MORC2 promotes colorectal cancer metastasis, through RBM39-mediated pre-CDK5RAP2 alternative splicing and highlight the MORC2/RBM39/CDK5RAP2 axis as a potential therapeutic target for colorectal cancer.

In addition, GSE173839, GSE25066, GSE41998, and GSE194040 dataset analyses of the underlying CCC signature suggested that durvalumab with olaparib and paclitaxel, taxane-anthracycline chemotherapy, neoadjuvant cyclophosphamide/doxorubicin with ixabepilone or paclitaxel, and immunotherapeutic strategies might be suitable for COAD patients with higher CCC score. Eventually, the GDSC database analysis showed that lower CCC scores were likely to be more sensitive to 5-fluorouracil, bosutinib, gemcitabine, gefitinib, methotrexate, mitomycin C, and temozolomide, while patients with higher CCC score seemed to have a higher level of sensitivity to bortezomib and elesclomol. The novel CCC signature exhibited a good ability for prognosis prediction for COAD patients, and the CCC score was found to be highly correlated with molecular features, immune-related characteristics, and therapeutic responses, which would greatly promote clinical management and precision medicine for COAD.